La Jolla Pharmaceutical OverviewTrack La Jolla Pharmaceutical's total revenue ($46M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2022
Trailing 12 months ending Jun 2022
La Jolla Pharmaceutical (LJPC) currently reports a total revenue of $46M as of June 2022. That compares with $70M in the prior-year period — down 33.8% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore La Jolla Pharmaceutical's total revenue history and peer comparisons.
La Jolla Pharmaceutical's total revenue decreased from $70M to $46M — a 33.8% year-over-year decrease (period ending June 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
La Jolla Pharmaceutical's total revenue of $46M is lower than the Healthcare sector average of $110B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
La Jolla Pharmaceutical reported $46M in total revenue as of June 2022. That compares with $70M in the prior-year period — down 33.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total revenue of $46M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for La Jolla Pharmaceutical, and consider following LJPC for alerts when major investors trade the stock.
